arcs pharmacovigilance update
TRANSCRIPT
ARCS Pharmacovigilance update
Richard Hill
Medical Officer, Signal Investigation Unit, PMSB, TGA
12 March 2015
Contents
• Patient support programs
• Reports from (social) media
• Information requests from TGA
• MedDRA coding
1
Patient support programs (PSP)
• Medicines Australia definition:
– a program run by a company with or without involvement from a health consumer organisation, with the aim of increasing patient compliance and positive patient health outcomes.
• Patient support programs include:
– call/information centres
– periodic contacts to ensure treatment compliance
– nurse visits for medication administration
– delivery of educational materials
• Features of PSPs:
– not designed to collect adverse event information
– may be managed by a third party
– may be long duration
2
PSP reports
• ADR reports from PSP are solicited reports
• ICH E2D:
– Solicited reports are those derived from organized data collection systems,
which include clinical trials, registries, post-approval named patient use
programs, other patient support and disease management programs,…
– solicited reports … should have an appropriate causality assessment by a
healthcare professional or an MAH
3
PSP reports
• Australian PV guideline:
– 1.2.2: Sponsors should have permanently and continuously at their
disposal a person in Australia responsible for pharmacovigilance... The
person responsible for pharmacovigilance should be experienced in
pharmacovigilance, and if not medically qualified, they should have ready
access to a medically qualified person
– 2.7.1 Minimum data elements:
an identifiable patient
one or more identifiable reporters
one or more suspected reactions
one or more suspected medicines
4
PSP reports
• Causality assessment must be performed (2.7.2):
5
PSP reports – example
• Was unable to be cannulated successfully. Received regular unspecified
infusions for his Crohn’s Disease.
6
PSP reports – example
• Patient received [] and thought she was having a stroke, her legs felt heavy
with leg spasms, very bad back pain and general pains.
7
PSP reports
• Reminder of general reporting requirements:
– follow-up as needed
– identify concomitant medications; suspect as appropriate
– non-serious reports do not have to be sent to TGA on an expedited basis
must be held on file by sponsor
must include in PSURs
8
Reports from (social) media
• These reports need to comply with mandatory requirements, especially
identifiable patient
• Media reports may be quite likely duplicates
• Media reports may be quite likely unusual ADRs
• PV guidelines 1.2.2:
– Sponsors should regularly screen internet or digital media under their
management or responsibility, for potential reports of suspected ARs.
9
Information from TGA
• Reminder of the information we can provide:
– line listings
– “public case details”
• Release of information must be approved by a senior medical officer
• Manual system at present
• Happy to work with sponsors to meet global reporting requirements
10
Common reporting/coding issues
Reports of overdose with no clear ADR
Case example:
• Initial Information was received from a health care professional and concerns a
96 year old Male patient who was treated with EPO-analogue for an unknown
indication. No concurrent conditions and medical history was reported. No
concomitant medications and past drugs were reported. On an unspecified
date, the patient had overdose of EPO-analogue. It was reported that a nurse
was contacted, who advised to monitor haemoglobin levels at about 95 hours
after administration.
No adverse event reported in association with overdose, no need to report!
11
Common reporting/coding issues
Reporting of neoplasm progression• Progressive disease in patients taking antineoplastic agents
Case example:
1. “On an unspecified date the patient started antineoplastic drug (dose, route,
form, frequency: not reported). On an unspecified date therapy with drug was
discontinued. On an unspecified date, the patient once again developed
disease relapsed in lungs and lymph glands.”
2. “On an unknown date he started treatment with antineoplastic drug. The
patient died on 12 June 2012 from cancer”
No need to report!
12
Common reporting/coding issues
Reports where role of drug in ADR is unclear
Case example:
• “The patient was treated with drug-x, dose, dates and frequency unspecified, for
ankylosing spondylitis. The patient stopped drug-x and decided to try drug-y for
convenience while travelling. The patient reported that drug-y gave reasonable
control, but he felt drug-x helped his ankylosing spondylitis more. The patient
began treatment with drug-x, again, dose, dates and frequency unspecified.
• On 06-AUG-2012, a right hip replacement was performed. The patient was
recovering from right hip replacement. The reporter did not provide causality
between right hip replacement and drug-x.”
• Coded by sponsor as [hip arthroplasty], however no clear relationship between hip
replacement and suspect drug
13
Common reporting/coding issues
Reports where role of drug in ADR is unclear
Case example:
• “The patient was admitted to hospital 21-Dec-2008, where she had fluid drained from her
abdomen due to a chronic liver condition. The patient had been on the liver transplant list since
August 2008. She was also suffering from pneumonia and was given increasing levels of pain-
relieving drug and other pain medication. Dose, date and route of administration of drug were
not reported.”
• “On 26-Dec-2008, just hours before she was discharged, the patient had vomited and was
oozing a “moderate amount” of fluid from a drain site on her side. The patient had passed
“dark, concentrated urine” and had a bloated abdomen. The patient was released on 26-Dec-
2008, blood test results showed a clear deterioration in her renal function. Her condition
worsened and she returned to hospital on 27-Dec-2008 before dying there on 29-Dec-2008.
The primary cause of death was listed as multi-organ failure.”
• Sponsor coded terms: [multiorgan failure; renal impairment; urine colour abnormal; abdominal
distension; vomiting; post-procedural drainage], however no clear relationship with suspect
drug.14
Common reporting/coding issues
Reporting of death of unknown cause or unrelated to drug• Information too limited to assess causality
• Sponsors should attempt to obtain more information if possible
Case example:
1. “The patient received drug for an unspecified indication. On an unspecified
date, the patient was deceased . Cause of death was not provided.”
2. “On 20 Aug 2012, while on drug, the patient passed away. The patient wasn’t
admitted to hospital, passed away at nursing home. No other details known.
The patient had a past medical history of previous silent myocardial infarction
and chronic obstructive pulmonary disease.”
15
Common reporting/coding issues
Reports with reaction terms not related to drug
Case example:
• “Initial consumer report received on 17 Jul 2012. An elderly female consumer used topical drug
to help with shoulder pain caused by a pre-existing injury. She has been applying the product
to the shoulder approximately 3 times a day when needed, on and off, for a number of years.
She stated they do not use topical drug for longer than 2 weeks at a time. She finds the topical
drug very effective at relieving the pain. The patient’s doctor advised her to use the product
while awaiting shoulder surgery. On the patient’s recent visit to her surgeon they identified the
bone in the shoulder was brittle and calcification had occurred making her ineligible for
surgery. No treatment was necessary. Final outcome was reported as reaction continues. No
other information provided.”
• Coded by sponsor as [articular calcification] – related to underlying disease and [osteogenesis
imperfecta] – genetic disorder, unrelated to drug
16
Common reporting/coding issues
Reports with reaction terms not related to drug
Case example:
• Initial information was received from a physician in Australia concerning a
female patient who was on an anticoagulant (formulation, dosage, frequency,
indication, dates of therapy not reported). On an unreported date, the patient
had a car accident and the hospital was unable to stop the bleeding. The
patient is in a critical condition. Several specialists involved are trying to stop
the bleeding. Information on the treatment provided, if any, was not reported.
The outcome of the event was not reported.
• Sponsor coded terms: [road traffic accident] [wound haemorrhage]
• TGA coded term: [haemorrhage]
17
Common reporting/coding issues
Reports with reaction terms coded that relate to the underlying disease being treated
Case example:
• “On unspecified date, the patient started therapy with monoclonal antibody and chemotherapy
agent. On an unspecified date, therapy with chemotherapy agent was stopped due to toxicity.
It was reported that the patient had stopped therapy with monoclonal antibody due to financial
constraints and since then she had developed a increased ascites and increased
lymphoedema of both legs. The company assessed the events toxicity and increased
lymphoedema of both legs as medically significant and increased ascites as non-serious. No
further information was reported.”
• Sponsor coding: [drug toxicity] [lymphoedema] [ascites];
suspect drugs [monoclonal antibody] [chemotherapy agent]
• TGA coding: [drug toxicity]; suspect drug [chemotherapy agent]
18
Common reporting/coding issues
Reports with no clear temporal relationship/implausible
temporal relationship to suspect drug
Case example:
• “On an unreported date, after about 4 days of anticoagulant, the patient
developed melaena and was sent to hospital where he received a transfusion.
The patient experienced a colon haemorrhage and tubulovillous adenoma was
found.”
• Sponsor coding: [melaena] [colon haemorrhage] [colon adenoma]
• TGA coding: [melaena] [colon haemorrhage]
19
Common reporting/coding issues
Past history coded as ADR
Case example:
• “This report refers to an elderly patient of unspecified gender ... On an
unknown date, the patient reported that the blood pressure had raised in the
morning ... The patient reported having had scarlet fever which had a similar
effect.”
• Sponsor coding coding: [blood pressure increased] [scarlet fever]
• TGA coding: [blood pressure increased]
20
TGA coding conventions
Condition aggravated / disease progression• Some PTs have a “disease aggravated” / “disease progression” LLT – diabetes
• However, some do not – cancer pain
• Since the PT is shown on DAEN and routine searches, information from the
LLT is lost
• Prefer to use the general PTs “Condition aggravated”, “Disease progression”,
“Concomitant disease aggravated”, etc.
21
TGA coding conventions
• ADRS database doesn’t have strong mother-child linkage
• Use of the terms “Maternal exposure during pregnancy”, “Foetal exposure
during pregnancy” helps to clarify the story
22
Thank you
Questions?
23